FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

A correction has been published: N Engl J Med 2001;344(9):686.

Volume 343:1350-1354 November 9, 2000 Number 19 Next

	Full Text PDF Editorial by Weinstein, J. N. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Buckner, J. C. PubMed Citation

ABSTRACT

Background The DNA-repair enzyme O ⁶-methylguanine-DNA methyltransferase (MGMT) inhibits the killing of tumor cells by alkylating agents. MGMT activity is controlled by a promoter; methylation of the promoter silences the gene in cancer, and the cells no longer produce MGMT. We examined gliomas to determine whether methylation of the MGMT promoter is related to the responsiveness of the tumor to alkylating agents.

Methods We analyzed the MGMT promoter in tumor DNA by a methylation-specific polymerase-chain-reaction assay. The gliomas were obtained from patients who had been treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, or BCNU). The molecular data were correlated with the clinical outcome.

Results The MGMT promoter was methylated in gliomas from 19 of 47 patients (40 percent). This finding was associated with regression of the tumor and prolonged overall and disease-free survival. It was an independent and stronger prognostic factor than age, stage, tumor grade, or performance status.

Conclusions Methylation of the MGMT promoter in gliomas is a useful predictor of the responsiveness of the tumors to alkylating agents.

Source Information

From the Divisions of Cancer Biology (M.E., S.B.B., J.G.H.) and Biostatistics (S.N.G.), Johns Hopkins Oncology Center, Baltimore; and the Biotechnology Laboratory, Cell Therapy Area, Department of Oncology, Clinica Universitaria, Pamplona, Spain (J.G.-F., E.A., O.F.H., V.V.).

Address reprint requests to Dr. Herman at the Johns Hopkins Oncology Center, 1650 Orleans, Baltimore, MD 21231, or at hermanji{at}jhmi.edu.

Full Text of this Article

This article has been cited by other articles:

• Spiegl-Kreinecker, S., Pirker, C., Filipits, M., Lotsch, D., Buchroithner, J., Pichler, J., Silye, R., Weis, S., Micksche, M., Fischer, J., Berger, W. (2009). O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncology 0: nop003v1-nop003 [Abstract] [Full Text]  
• Candiloro, I. L.M., Dobrovic, A. (2009). Detection of MGMT Promoter Methylation in Normal Individuals Is Strongly Associated with the T Allele of the rs16906252 MGMT Promoter Single Nucleotide Polymorphism. Cancer Prevention Research 2: 862-867 [Abstract] [Full Text]  
• Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., El Hallani, S., Boisselier, B., Mokhtari, K., Hoang-Xuan, K., Delattre, J.-Y. (2009). Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas. JCO 27: 4150-4154 [Abstract] [Full Text]  
• Elias, A., Siegelin, M. D., Steinmuller, A., von Deimling, A., Lass, U., Korn, B., Mueller, W. (2009). Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Gliomas. Clin. Cancer Res. 15: 5457-5465 [Abstract] [Full Text]  
• Hegi, M. E., Sciuscio, D., Murat, A., Levivier, M., Stupp, R. (2009). Epigenetic Deregulation of DNA Repair and Its Potential for Therapy. Clin. Cancer Res. 15: 5026-5031 [Abstract] [Full Text]  
• Bailey, V. J., Easwaran, H., Zhang, Y., Griffiths, E., Belinsky, S. A., Herman, J. G., Baylin, S. B., Carraway, H. E., Wang, T.-H. (2009). MS-qFRET: A quantum dot-based method for analysis of DNA methylation. Genome Res 19: 1455-1461 [Abstract] [Full Text]  
• Yip, S., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., Louis, D. N. (2009). MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance. Clin. Cancer Res. 15: 4622-4629 [Abstract] [Full Text]  
• MELLAI, M., CALDERA, V., ANNOVAZZI, L., CHIO, A., LANOTTE, M., CASSONI, P., FINOCCHIARO, G., SCHIFFER, D. (2009). MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas. Cancer Genomics Proteomics 6: 219-227 [Abstract] [Full Text]  
• McCabe, M. T., Brandes, J. C., Vertino, P. M. (2009). Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications. Clin. Cancer Res. 15: 3927-3937 [Abstract] [Full Text]  
• Cui, B., Johnson, S. P., Bullock, N., Ali-Osman, F., Bigner, D. D., Friedman, H. S. (2009). Bifunctional DNA Alkylator 1,3-Bis(2-chloroethyl)-1-nitrosourea Activates the ATR-Chk1 Pathway Independently of the Mismatch Repair Pathway. Mol. Pharmacol. 75: 1356-1363 [Abstract] [Full Text]  
• Hervouet, E., Debien, E., Campion, L., Charbord, J., Menanteau, J., Vallette, F. M., Cartron, P.-F. (2009). Folate Supplementation Limits the Aggressiveness of Glioma via the Remethylation of DNA Repeats Element and Genes Governing Apoptosis and Proliferation. Clin. Cancer Res. 15: 3519-3529 [Abstract] [Full Text]  
• Seligson, D. B., Horvath, S., McBrian, M. A., Mah, V., Yu, H., Tze, S., Wang, Q., Chia, D., Goodglick, L., Kurdistani, S. K. (2009). Global Levels of Histone Modifications Predict Prognosis in Different Cancers. Am. J. Pathol. 174: 1619-1628 [Abstract] [Full Text]  
• Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., McLendon, R. E., Herndon, J. E. II, Walker, A., Friedman, H. S. (2009). Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma. JCO 27: 1262-1267 [Abstract] [Full Text]  
• Quinn, J. A., Jiang, S. X., Carter, J., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., McLendon, R. E., Herndon, J. E. II, Threatt, S., Friedman, H. S. (2009). Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme. Clin. Cancer Res. 15: 1064-1068 [Abstract] [Full Text]  
• Wick, W., Platten, M., Weller, M. (2009). New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol Duke 11: 69-79 [Abstract] [Full Text]  
• Vredenburgh, J. J., Desjardins, A., Reardon, D. A., Friedman, H. S. (2009). Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol Duke 11: 80-91 [Abstract] [Full Text]  
• Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., Sarkaria, J. N. (2009). Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol Duke 11: 281-291 [Abstract] [Full Text]  
• Everhard, S., Tost, J., El Abdalaoui, H., Criniere, E., Busato, F., Marie, Y., Gut, I. G., Sanson, M., Mokhtari, K., Laigle-Donadey, F., Hoang-Xuan, K., Delattre, J.-Y., Thillet, J. (2009). Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol Duke 11: 348-356 [Abstract] [Full Text]  
• Schaich, M., Kestel, L., Pfirrmann, M., Robel, K., Illmer, T., Kramer, M., Dill, C., Ehninger, G., Schackert, G., Krex, D. (2009). A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 20: 175-181 [Abstract] [Full Text]  
• Hartmann, O., Spyratos, F., Harbeck, N., Dietrich, D., Fassbender, A., Schmitt, M., Eppenberger-Castori, S., Vuaroqueaux, V., Lerebours, F., Welzel, K., Maier, S., Plum, A., Niemann, S., Foekens, J. A., Lesche, R., Martens, J. W.M. (2009). DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy. Clin. Cancer Res. 15: 315-323 [Abstract] [Full Text]  
• Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., Geoffroy, F. J., Arusell, R., Kitange, G., Jenkins, R. B., Kugler, J. W., Morton, R. F., Rowland, K. M. Jr, Mischel, P., Yong, W. H., Scheithauer, B. W., Schiff, D., Giannini, C., Buckner, J. C. (2008). Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177. JCO 26: 5603-5609 [Abstract] [Full Text]  
• Duffy, M. J., Crown, J. (2008). A Personalized Approach to Cancer Treatment: How Biomarkers Can Help. Clin. Chem. 54: 1770-1779 [Abstract] [Full Text]  
• Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., Gilbert, M. R. (2008). Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. JCO 26: 4189-4199 [Abstract] [Full Text]  
• Mason, W. P., Cairncross, J. G. (2008). Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas. Neurology 71: 365-373 [Abstract] [Full Text]  
• Yamauchi, T., Ogawa, M., Ueda, T. (2008). Carmustine-Resistant Cancer Cells Are Sensitized to Temozolomide As A Result of Enhanced Mismatch Repair during the Development of Carmustine Resistance. Mol. Pharmacol. 74: 82-91 [Abstract] [Full Text]  
• Vlassenbroeck, I., Califice, S., Diserens, A.-C., Migliavacca, E., Straub, J., Di Stefano, I., Moreau, F., Hamou, M.-F., Renard, I., Delorenzi, M., Flamion, B., DiGuiseppi, J., Bierau, K., Hegi, M. E. (2008). Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma. J. Mol. Diagn. 10: 332-337 [Abstract] [Full Text]  
• Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., Wick, W. (2008). Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. Clin. Cancer Res. 14: 2900-2908 [Abstract] [Full Text]  
• Hadnagy, A., Beaulieu, R., Balicki, D. (2008). Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Molecular Cancer Therapeutics 7: 740-748 [Abstract] [Full Text]  
• Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., Glockner, S., Piantadosi, S., Gabrielson, E., Pridham, G., Pelosky, K., Belinsky, S. A., Yang, S. C., Baylin, S. B., Herman, J. G. (2008). DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer. NEJM 358: 1118-1128 [Abstract] [Full Text]  
• Esteller, M. (2008). Epigenetics in Cancer. NEJM 358: 1148-1159 [Full Text]  
• de Bont, J. M., Packer, R. J., Michiels, E. M., Boer, M. L. d., Pieters, R. (2008). Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective. Neuro Oncol Duke 10: 1040-1060 [Abstract] [Full Text]  
• Nagane, M., Kobayashi, K., Ohnishi, A., Shimizu, S., Shiokawa, Y. (2007). Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide. Jpn J Clin Oncol 0: hym132v1-10 [Abstract] [Full Text]  
• Shen, L., Kondo, Y., Ahmed, S., Boumber, Y., Konishi, K., Guo, Y., Chen, X., Vilaythong, J. N., Issa, J.-P. J. (2007). Drug Sensitivity Prediction by CpG Island Methylation Profile in the NCI-60 Cancer Cell Line Panel. Cancer Res. 67: 11335-11343 [Abstract] [Full Text]  
• Horton, T. M., Thompson, P. A., Berg, S. L., Adamson, P. C., Ingle, A. M., Dolan, M. E., Delaney, S. M., Hedge, M., Weiss, H. L., Wu, M.-F., Blaney, S. M. (2007). Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children's Oncology Group Study. JCO 25: 4922-4928 [Abstract] [Full Text]  
• Kholod, N., Boniver, J., Delvenne, P. (2007). A New Dimethyl Sulfoxide-Based Method for Gene Promoter Methylation Detection. J. Mol. Diagn. 9: 574-581 [Abstract] [Full Text]  
• Fontijn, D., Adema, A. D., Bhakat, K. K., Pinedo, H. M., Peters, G. J., Boven, E. (2007). O6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells. Molecular Cancer Therapeutics 6: 2807-2815 [Abstract] [Full Text]  
• Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., Weller, M., Schackert, G., for the German Glioma Network, (2007). Long-term survival with glioblastoma multiforme. Brain 130: 2596-2606 [Abstract] [Full Text]  
• Lavon, I., Fuchs, D., Zrihan, D., Efroni, G., Zelikovitch, B., Fellig, Y., Siegal, T. (2007). Novel Mechanism whereby Nuclear Factor {kappa}B Mediates DNA Damage Repair through Regulation of O6-Methylguanine-DNA-Methyltransferase. Cancer Res. 67: 8952-8959 [Abstract] [Full Text]  
• Stupp, R., Hegi, M. E., Gilbert, M. R., Chakravarti, A. (2007). Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. JCO 25: 4127-4136 [Abstract] [Full Text]  
• Lonning, P., Knappskog, S, Staalesen, V, Chrisanthar, R, Lillehaug, J. (2007). Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 18: 1293-1306 [Abstract] [Full Text]  
• Mikeska, T., Bock, C., El-Maarri, O., Hubner, A., Ehrentraut, D., Schramm, J., Felsberg, J., Kahl, P., Buttner, R., Pietsch, T., Waha, A. (2007). Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis. J. Mol. Diagn. 9: 368-381 [Abstract] [Full Text]  
• Ranson, M., Hersey, P., Thompson, D., Beith, J., McArthur, G. A., Haydon, A., Davis, I. D., Kefford, R. F., Mortimer, P., Harris, P. A., Baka, S., Seebaran, A., Sabharwal, A., Watson, A. J., Margison, G. P., Middleton, M. R. (2007). Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma. JCO 25: 2540-2545 [Abstract] [Full Text]  
• Martinez, R., Setien, F., Voelter, C., Casado, S., Quesada, M. P., Schackert, G., Esteller, M. (2007). CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 28: 1264-1268 [Abstract] [Full Text]  
• Eoli, M., Menghi, F., Bruzzone, M. G., De Simone, T., Valletta, L., Pollo, B., Bissola, L., Silvani, A., Bianchessi, D., D'Incerti, L., Filippini, G., Broggi, G., Boiardi, A., Finocchiaro, G. (2007). Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival. Clin. Cancer Res. 13: 2606-2613 [Abstract] [Full Text]  
• Stupp, R., Hegi, M. E. (2007). Methylguanine Methyltransferase Testing in Glioblastoma: When and How?. JCO 25: 1459-1460 [Full Text]  
• Chinot, O. L., Barrie, M., Fuentes, S., Eudes, N., Lancelot, S., Metellus, P., Muracciole, X., Braguer, D., Ouafik, L., Martin, P.-M., Dufour, H., Figarella-Branger, D. (2007). Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide. JCO 25: 1470-1475 [Abstract] [Full Text]  
• Brena, R. M., Costello, J. F. (2007). Genome-epigenome interactions in cancer. Hum Mol Genet 16: R96-R105 [Abstract] [Full Text]  
• Wojdacz, T. K., Dobrovic, A. (2007). Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 35: e41-e41 [Abstract] [Full Text]  
• Reinhold, W. C., Reimers, M. A., Maunakea, A. K., Kim, S., Lababidi, S., Scherf, U., Shankavaram, U. T., Ziegler, M. S., Stewart, C., Kouros-Mehr, H., Cui, H., Dolginow, D., Scudiero, D. A., Pommier, Y. G., Munroe, D. J., Feinberg, A. P., Weinstein, J. N. (2007). Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Molecular Cancer Therapeutics 6: 391-403 [Abstract] [Full Text]  
• Samuels, M. A. (2007). Update in Neurology. ANN INTERN MED 146: 128-132 [Full Text]  
• Brandes, A. A., Tosoni, A., Cavallo, G., Reni, M., Franceschi, E., Bonaldi, L., Bertorelle, R., Gardiman, M., Ghimenton, C., Iuzzolino, P., Pession, A., Blatt, V., Ermani, M. (2006). Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study. JCO 24: 4746-4753 [Abstract] [Full Text]  
• Maxwell, J. A., Johnson, S. P., Quinn, J. A., McLendon, R. E., Ali-Osman, F., Friedman, A. H., Herndon, J. E. II, Bierau, K., Bigley, J., Bigner, D. D., Friedman, H. S. (2006). Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.. Molecular Cancer Therapeutics 5: 2531-2539 [Abstract] [Full Text]  
• Herrlinger, U., Rieger, J., Koch, D., Loeser, S., Blaschke, B., Kortmann, R.-D., Steinbach, J. P., Hundsberger, T., Wick, W., Meyermann, R., Tan, T.-C., Sommer, C., Bamberg, M., Reifenberger, G., Weller, M. (2006). Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. JCO 24: 4412-4417 [Abstract] [Full Text]  
• Fruehauf, J. P., Brem, H., Brem, S., Sloan, A., Barger, G., Huang, W., Parker, R. (2006). In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas. Clin. Cancer Res. 12: 4523-4532 [Abstract] [Full Text]  
• Pollack, I. F., Hamilton, R. L., Sobol, R. W., Burnham, J., Yates, A. J., Holmes, E. J., Zhou, T., Finlay, J. L. (2006). O6-Methylguanine-DNA Methyltransferase Expression Strongly Correlates With Outcome in Childhood Malignant Gliomas: Results From the CCG-945 Cohort. JCO 24: 3431-3437 [Abstract] [Full Text]  
• Foltz, G., Ryu, G.-Y., Yoon, J.-G., Nelson, T., Fahey, J., Frakes, A., Lee, H., Field, L., Zander, K., Sibenaller, Z., Ryken, T. C., Vibhakar, R., Hood, L., Madan, A. (2006). Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma.. Cancer Res. 66: 6665-6674 [Abstract] [Full Text]  
• Berger, Y., Bernasconi, C. C., Juillerat-Jeanneret, L. (2006). Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents.. Exp. Biol. Med. 231: 1111-1119 [Abstract] [Full Text]  
• Esteller, M. (2006). The necessity of a human epigenome project. Carcinogenesis 27: 1121-1125 [Abstract] [Full Text]  
• Gagnon, J.-F., Bernard, O., Villeneuve, L., Tetu, B., Guillemette, C. (2006). Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer. Clin. Cancer Res. 12: 1850-1858 [Abstract] [Full Text]  
• Reardon, D. A., Rich, J. N., Friedman, H. S., Bigner, D. D. (2006). Recent Advances in the Treatment of Malignant Astrocytoma. JCO 24: 1253-1265 [Abstract] [Full Text]  
• Neff, T., Beard, B. C., Kiem, H.-P. (2006). Survival of the fittest: in vivo selection and stem cell gene therapy. Blood 107: 1751-1760 [Abstract] [Full Text]  
• Fox, E. J., Leahy, D. T., Geraghty, R., Mulcahy, H. E., Fennelly, D., Hyland, J. M., O'Donoghue, D. P., Sheahan, K. (2006). Mutually Exclusive Promoter Hypermethylation Patterns of hMLH1 and O6-Methylguanine DNA Methyltransferase in Colorectal Cancer. J. Mol. Diagn. 8: 68-75 [Abstract] [Full Text]  
• Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., Cairncross, J. G., on behalf of the European Organisation for Researc, (2006). Changing paradigms--an update on the multidisciplinary management of malignant glioma.. The Oncologist 11: 165-180 [Abstract] [Full Text]  
• Bredel, M., Bredel, C., Juric, D., Duran, G. E., Yu, R. X., Harsh, G. R., Vogel, H., Recht, L. D., Scheck, A. C., Sikic, B. I. (2006). Tumor Necrosis Factor-{alpha}-Induced Protein 3 As a Putative Regulator of Nuclear Factor-{kappa}B-Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas. JCO 24: 274-287 [Abstract] [Full Text]  
• Aghi, M., Rabkin, S., Martuza, R. L. (2006). Effect of Chemotherapy-Induced DNA Repair on Oncolytic Herpes Simplex Viral Replication. JNCI J Natl Cancer Inst 98: 38-50 [Abstract] [Full Text]  
• Mori, T., O'Day, S. J., Umetani, N., Martinez, S. R., Kitago, M., Koyanagi, K., Kuo, C., Takeshima, T.-L., Milford, R., Wang, H.-J., Vu, V. D., Nguyen, S. L., Hoon, D. S.B. (2005). Predictive Utility of Circulating Methylated DNA in Serum of Melanoma Patients Receiving Biochemotherapy. JCO 23: 9351-9358 [Abstract] [Full Text]  
• Hansen, R. J., Nagasubramanian, R., Delaney, S. M., Cherian, M. M., Lin, S., Kogan, S. C., Dolan, M. E. (2005). Role of O6-Alkylguanine-DNA Alkyltransferase in Protecting against 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-Induced Long-Term Toxicities. J. Pharmacol. Exp. Ther. 315: 1247-1255 [Abstract] [Full Text]  
• Sadee, W., Dai, Z. (2005). Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 14: R207-R214 [Abstract] [Full Text]  
• Chan, M. W.Y., Wei, S. H., Wen, P., Wang, Z., Matei, D. E., Liu, J. C., Liyanarachchi, S., Brown, R., Nephew, K. P., Yan, P. S., Huang, T. H-M. (2005). Hypermethylation of 18S and 28S Ribosomal DNAs Predicts Progression-Free Survival in Patients with Ovarian Cancer. Clin. Cancer Res. 11: 7376-7383 [Abstract] [Full Text]  
• Quinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J., Rich, J., Friedman, A. H., Reardon, D. A., Sampson, J. H., Pegg, A. E., Moschel, R. C., Birch, R., McLendon, R. E., Provenzale, J. M., Gururangan, S., Dancey, J. E., Maxwell, J., Tourt-Uhlig, S., Herndon, J. E. II, Bigner, D. D., Friedman, H. S. (2005). Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma. JCO 23: 7178-7187 [Abstract] [Full Text]  
• Natsume, A., Ishii, D., Wakabayashi, T., Tsuno, T., Hatano, H., Mizuno, M., Yoshida, J. (2005). IFN-{beta} Down-Regulates the Expression of DNA Repair Gene MGMT and Sensitizes Resistant Glioma Cells to Temozolomide. Cancer Res. 65: 7573-7579 [Abstract] [Full Text]  
• Brell, M., Tortosa, A., Verger, E., Gil, J. M., Vinolas, N., Villa, S., Acebes, J. J., Caral, L., Pujol, T., Ferrer, I., Ribalta, T., Graus, F. (2005). Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas. Clin. Cancer Res. 11: 5167-5174 [Abstract] [Full Text]  
• Dimopoulos, M. A., Souliotis, V. L., Anagnostopoulos, A., Papadimitriou, C., Sfikakis, P. P. (2005). Extent of Damage and Repair in the p53 Tumor-Suppressor Gene After Treatment of Myeloma Patients With High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predict Clinical Outcome. JCO 23: 4381-4389 [Abstract] [Full Text]  
• van Doorn, R., Zoutman, W. H., Dijkman, R., de Menezes, R. X., Commandeur, S., Mulder, A. A., van der Velden, P. A., Vermeer, M. H., Willemze, R., Yan, P. S., Huang, T. H., Tensen, C. P. (2005). Epigenetic Profiling of Cutaneous T-Cell Lymphoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes Including BCL7a, PTPRG, and p73. JCO 23: 3886-3896 [Abstract] [Full Text]  
• Miyamoto, K., Ushijima, T. (2005). Diagnostic and Therapeutic Applications of Epigenetics. Jpn J Clin Oncol 35: 293-301 [Abstract] [Full Text]  
• Laird, P. W. (2005). Cancer epigenetics. Hum Mol Genet 14: R65-R76 [Abstract] [Full Text]  
• Kohonen-Corish, M. R.J., Daniel, J. J., Chan, C., Lin, B. P.C., Kwun, S. Y., Dent, O. F., Dhillon, V. S., Trent, R. J.A., Chapuis, P. H., Bokey, E. L. (2005). Low Microsatellite Instability Is Associated With Poor Prognosis in Stage C Colon Cancer. JCO 23: 2318-2324 [Abstract] [Full Text]  
• Alaminos, M., Davalos, V., Ropero, S., Setien, F., Paz, M. F., Herranz, M., Fraga, M. F., Mora, J., Cheung, N.-K. V., Gerald, W. L., Esteller, M. (2005). EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma. Cancer Res. 65: 2565-2571 [Abstract] [Full Text]  
• Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J.B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., Mirimanoff, R. O., the European Organisation for Research and Treatme, (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. NEJM 352: 987-996 [Abstract] [Full Text]  
• Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., Bromberg, J. E.C., Hau, P., Mirimanoff, R. O., Cairncross, J. G., Janzer, R. C., Stupp, R. (2005). MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. NEJM 352: 997-1003 [Abstract] [Full Text]  
• Osanai, T., Takagi, Y., Toriya, Y., Nakagawa, T., Aruga, T., Iida, S., Uetake, H., Sugihara, K. (2005). Inverse Correlation Between the Expression of O6-Methylguanine-DNA Methyl Transferase (MGMT) and p53 in Breast Cancer. Jpn J Clin Oncol 35: 121-125 [Abstract] [Full Text]  
• Fukushima, T., Katayama, Y., Watanabe, T., Yoshino, A., Ogino, A., Ohta, T., Komine, C. (2005). Promoter Hypermethylation of Mismatch Repair Gene hMLH1 Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea. Clin. Cancer Res. 11: 1539-1544 [Abstract] [Full Text]  
• Neff, T., Beard, B. C., Peterson, L. J., Anandakumar, P., Thompson, J., Kiem, H.-P. (2005). Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 105: 997-1002 [Abstract] [Full Text]  
• Danam, R. P., Howell, S. R., Brent, T. P., Harris, L. C. (2005). Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Molecular Cancer Therapeutics 4: 61-69 [Abstract] [Full Text]  
• Liu, T. F., Hall, P. D., Cohen, K. A., Willingham, M. C., Cai, J., Thorburn, A., Frankel, A. E. (2005). Interstitial Diphtheria Toxin-Epidermal Growth Factor Fusion Protein Therapy Produces Regressions of Subcutaneous Human Glioblastoma Multiforme Tumors in Athymic Nude Mice. Clin. Cancer Res. 11: 329-334 [Abstract] [Full Text]  
• Bobola, M. S., Emond, M. J., Blank, A., Meade, E. H., Kolstoe, D. D., Berger, M. S., Rostomily, R. C., Silbergeld, D. L., Spence, A. M., Silber, J. R. (2004). Apurinic Endonuclease Activity in Adult Gliomas and Time to Tumor Progression after Alkylating Agent-Based Chemotherapy and after Radiotherapy. Clin. Cancer Res. 10: 7875-7883 [Abstract] [Full Text]  
• Das, P. M., Singal, R. (2004). DNA Methylation and Cancer. JCO 22: 4632-4642 [Abstract] [Full Text]  
• Stone, A. R., Bobo, W., Brat, D. J., Devi, N. S., Van Meir, E. G., Vertino, P. M. (2004). Aberrant Methylation and Down-Regulation of TMS1/ASC in Human Glioblastoma. Am. J. Pathol. 165: 1151-1161 [Abstract] [Full Text]  
• Paz, M. F., Yaya-Tur, R., Rojas-Marcos, I., Reynes, G., Pollan, M., Aguirre-Cruz, L., Garcia-Lopez, J. L., Piquer, J., Safont, M.-J., Balana, C., Sanchez-Cespedes, M., Garcia-Villanueva, M., Arribas, L., Esteller, M. (2004). CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas. Clin. Cancer Res. 10: 4933-4938 [Abstract] [Full Text]  
• Rood, B. R., Zhang, H., Cogen, P. H. (2004). Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma. Neuro Oncol Duke 6: 200-207 [Abstract]  
• Zuo, C., Ai, L., Ratliff, P., Suen, J. Y., Hanna, E., Brent, T. P., Fan, C.-Y. (2004). O6-Methylguanine-DNA Methyltransferase Gene: Epigenetic Silencing and Prognostic Value in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiol. Biomarkers Prev. 13: 967-975 [Abstract] [Full Text]  
• Pakneshan, P., Tetu, B., Rabbani, S. A. (2004). Demethylation of Urokinase Promoter as a Prognostic Marker in Patients with Breast Carcinoma. Clin. Cancer Res. 10: 3035-3041 [Abstract] [Full Text]  
• Mori, Y., Yin, J., Sato, F., Sterian, A., Simms, L. A., Selaru, F. M., Schulmann, K., Xu, Y., Olaru, A., Wang, S., Deacu, E., Abraham, J. M., Young, J., Leggett, B. A., Meltzer, S. J. (2004). Identification of Genes Uniquely Involved in Frequent Microsatellite Instability Colon Carcinogenesis by Expression Profiling Combined with Epigenetic Scanning. Cancer Res. 64: 2434-2438 [Abstract] [Full Text]